Bénéfices/risques, pratiques professionnelles et approche médico-économique du nivolumab et Cancer du Rein à Cellules Claires (CRCC)

Françoise Grudé, Fanny Marhuenda, Delphine Deniel Lagadec, Elouen Boughalem, Friederike Schlurmann, Claude El Kouri, Gildas Appéré and Muriel Travers ()
Additional contact information
Françoise Grudé: Observatoire dédié au Cancer
Fanny Marhuenda: Observatoire dédié au Cancer
Delphine Deniel Lagadec: Observatoire dédié au Cancer
Elouen Boughalem: UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes] - UNICANCER
Friederike Schlurmann: CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
Claude El Kouri: Hôpital privé du Confluent [Nantes]
Muriel Travers: Nantes Univ - Nantes Université

Post-Print from HAL

Date: 2018-11-29
References: Add references at CitEc
Citations:

Published in XVIIèmes Journées du GPCO, Nov 2018, Villejuif, France

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04491032

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().